#USA #New Jersey #Class Action #Securities Fraud #ADMA Biologics

ADMA Biologics Class Action Lawsuit Overview

A significant legal development has emerged in the biopharmaceutical sector as ADMA Biologics, Inc. faces a class action lawsuit alleging securities fraud. The lawsuit, filed by the prominent securities law firm Bleichmar Fonti & Auld LLP, is on behalf of investors who have suffered losses due to the dramatic decline in ADMA's stock price.

Background of the Lawsuit

On March 24, 2026, ADMA Biologics experienced a drastic stock plunge of 29% after Culper Research released a report accusing the company of engaging in a channel stuffing scheme. This alleged practice involved pushing excessive inventory onto distributors in a bid to artificially inflate revenue numbers. The report suggested that ADMA's claimed growth of 20% for the year 2025 was misleading due to these questionable tactics.

Key Details of the Litigation

• - Lead Plaintiff Deadline: Investors have until August 10, 2026, to submit requests to lead the case.
• - Court: U.S. District Court for the District of New Jersey.
• - Allegations: The lawsuit cites violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, reflecting serious breaches of securities laws.
• - Impact on Investors: The lawsuit comes at a time when investors are actively seeking recourse for their significant losses attributed to the stock's unsustainable rise prior to the downturn.

What Led to Stock Decline

Culper Research's report brought to light that ADMA allegedly incentivized a distributor to hoard excess inventory of ASCENIV, its flagship product, by offering rebates and extended payment terms. This practice misled investors by creating a facade of growth that was not backed by actual sales. Following the publication of these allegations, ADMA's stock fell from $13.59 to $11.33 on March 24, 2026, translating to a 16.6% drop, further declining to $8.29 by March 29, 2026.

What Should Investors Do?

For current or former investors of ADMA Biologics who believe they have been affected by this situation, it is crucial to understand their legal rights. Bleichmar Fonti & Auld LLP emphasizes that there is no upfront cost for representation. All legal fees will be contingent upon the success of the lawsuit, meaning that investors will not bear any litigation costs unless a favorable outcome is achieved.

Those interested in more information about this lawsuit or those wishing to participate are encouraged to visit the law firm's dedicated webpage that outlines the class action details and provides avenues for legal consultation.

About ADMA Biologics

ADMA Biologics is recognized for its focus on producing specialized biopharmaceuticals, with ASCENIV being a key product designed to treat Primary Humoral Immunodeficiency. The company has positioned itself in the sector with an emphasis on manufacturing and marketing biopharmaceutical solutions, but the current allegations may significantly impact its reputation and operational status.

Conclusion

As the legal proceedings unfold, ADMA Biologics and its stakeholders are facing a challenging period. The class action lawsuit brings to the forefront critical questions regarding compliance with securities regulations and the integrity of financial reporting in the pharmaceutical industry. It will be interesting to see how this case develops and what it means for shareholders and the industry as a whole.